Medtronic: Doing Just What the Doctors Order
Medtronic has recruited physician opinion leaders for strategic management positions in most of its operating divisions. The company believes this strategy will help bring them closer to customers and expedite the bedside-to-bench process for developing new products.
You may also be interested in...
An interview with retiring Medtronic CEO Bill Hawkins.
For a number of reasons, 2009 was a big year for the atrial fibrillation ablation market. Early in the year, Biosense Webster received FDA approval for its radiofrequency ablation catheter, the first such device to launch in the US with a specific AF indication. That approval was much more than just a landmark event for J&J; it changed the landscape of the AF industry, reinvigorating interest in the funding and development of new catheter-based technologies--a trend that has extended through to 2010 and will likely continue in the years ahead.
Among the most extraordinary developments both in clinical medicine and in the medical device industry over the past 30 years has been the birth and growth of interventional cardiology. IN VIVO remembers Donald Baim, one of the pioneers of the field, who died on November 6, 2009 at the age of 60.